Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $13.41M fell 12.9% year over year, behind the -3.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +16.6% a year.
Context
- Depreciation & amortization amounted to 32.6% of revenue in FY2025, up 10.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.9% toward the trailing-twelve-month pace of -3.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 60.47M USD
- Year-over-year change
- +6.3%
- 4-year CAGR
- +25.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.47M | +6.3% |
| FY2024 | 2024-12-31 | 56.87M | +16.6% |
| FY2023 | 2023-12-31 | 48.78M | +28.0% |
| FY2022 | 2022-12-31 | 38.1M | +53.9% |
| FY2021 | 2021-12-31 | 24.75M | — |
Depreciation & Amortization vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 depreciation & amortization of $56.96M is the 5th highest of the 9 companies compared; the peer median is $76.63M.
- Its year-over-year change of -3.2% is the highest of 9, against a peer median of -16.2%.
- Depreciation & amortization amounts to 27.3% of revenue for MRVI, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Aug 2026 | $116.35M | -6.9% | +8.7% | 13.2% | |
| LTM Jun 2026 | $97.31M | -7.0% | +19.4% | 12.4% | |
| LTM Sep 2026 | $96.75M | -8.8% | -3.2% | 7.9% | |
| LTM Jun 2026 | $56.96M | -3.2% | +16.6% | 27.3% | |
| LTM Sep 2026 | $56.52M | -7.7% | — | 9.1% | |
| LTM Mar 2026 | $17.69M | -95.7% | +207.8% | 11.1% | |
| LTM Mar 2026 | $6.29M | -60.3% | -22.5% | 7.3% | |
| LTM Mar 2026 | $4.8M | -38.2% | -38.3% | 4.8% | |
| Peer median (excluding MRVI) | $76.63M | -16.2% | +6.4% | 8.5% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 799.24M | 883M | 288.95M | 259.19M | 185.74M |
| Cost of Revenue | 140.56M | 168.96M | 148.74M | 150.88M | 152.35M |
| Gross Profit | 658.68M | 714.04M | 140.2M | 108.31M | 33.39M |
| Gross Margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.0% |
| Research & Development | 15.22M | 18.37M | 17.28M | 19.22M | 23.33M |
| Selling, General & Admin | 100.06M | 129.26M | 151.39M | 161.77M | 171.47M |
| Operating Expenses | 104.03M | 139.83M | 171.85M | 343.93M | 40.13M |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| EBITDA | 585.78M | 609.99M | 712.41M | (156.92M) | (147.51M) |
| EBITDA Margin | 73.3% | 69.1% | 246.6% | -60.5% | -79.4% |
| Operating Income | 554.65M | 574.22M | (31.65M) | (235.62M) | (6.74M) |
| Operating Margin | 69.4% | 65.0% | -11.0% | -90.9% | -3.6% |
| Interest Income | 0 | 2.34M | 27.73M | 27.4M | 23.95M |
| Interest Expense | 30.26M | 20.41M | 45.89M | 47.7M | 26.99M |
| Other Income / Expenses | (23.88M) | (22.74M) | 649.38M | (25.87M) | (228.24M) |
| Income Before Tax | 530.77M | 551.47M | 617.74M | (261.48M) | (234.97M) |
| Pre-Tax Margin | 66.4% | 62.5% | 213.8% | -100.9% | -126.5% |
| Income Tax Expense | 61.52M | 60.81M | 756.11M | (1.86M) | (4.21M) |
| Net Income | 182.04M | 220.21M | (119.03M) | (144.85M) | (130.77M) |
| Net Margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (Basic) | 1.59 | 1.67 | (0.90) | (1.05) | (0.91) |
| EPS (Diluted) | 1.56 | 1.67 | (0.90) | (1.05) | (0.91) |
| Weighted Avg Shares | 114.79M | 131.54M | 131.92M | 137.91M | 145.07M |
| Weighted Avg Shares (Diluted) | 121.97M | 131.7M | 131.92M | 137.91M | 145.07M |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.